does 503B actually matter or is it forum lore at this point
Slightly embarrassed to be asking this, but: does 503B actually matter or is it forum lore at this point.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
shortage status changes and the whole arrangement changes with it
What concentration is on the label, and does it match what you were expecting?
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
[removed by moderator]
a 503B has to register and report, so there is a paper trail to ask for
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
- 1Potency and sterility testing on the finished preparation are separate from…7 comments in this branch · started by u/mateusz_adebayo
- 2Not convinced. You are comparing a compounded concentration with a branded…7 comments in this branch · started by u/receptor_bias_rick